NIKKEI 225
38,073.98 -128.39 (-0.34%) HANG SENG
18,520.29 +206.43 (+1.13%) CRUDE OIL
79.36 +0.37 (+0.47%) GOLD FUTURES
2,323.60 +1.30 (+0.06%) DOW
39,056.39 +172.13 (+0.44%) Bitcoin GBP
49,392.55 -619.52 (-1.24%)
Vincerx Pharma, Inc. (VINC)
After hours:
| Previous close | 0.8172 |
| Open | 0.8350 |
| Bid | 0.8105 x 100 |
| Ask | 0.8342 x 100 |
| Day's range | 0.7870 - 0.8400 |
| 52-week range | 0.6100 - 9.3720 |
| Volume | |
| Avg. volume | 1,229,647 |
| Market cap | 24.513M |
| Beta (5Y monthly) | 1.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Vincerx (VINC) Tumbles on Results From Cancer Therapy Study
Though early-stage results on Vincerx's (VINC) experimental drug did show signs of anti-tumor activity, the share price drops as some analysts stated that the results were below expectations.
- Benzinga
Why Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday?
On Monday, Vincerx Pharma Inc (NASDAQ:VINC) presented preliminary Phase 1 data for VIP236 and updates on pipeline progress at the American Association for Cancer Research Annual Meeting 2024. VNC-236-101 is a Phase 1 dose-escalation study with monotherapy VIP236 for metastatic tumor patients who have exhausted all standard therapy options. Fifteen patients have been dosed to date on the once-every-three-weeks (Q3W) schedule: The Q3W schedule is well tolerated with no dose-limiting toxicity (DLT)
- GuruFocus.com
Vincerx Pharma Inc (VINC) Reports Q4 and Full Year 2023 Financials: A Close Look
Comparing Vincerx Pharma's Performance Against Analyst Estimates
